Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15708773 | 1.00 | NPC1 (0.67) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL20869625 | 0.93 | NPC1 (0.57) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL9187561 | 0.82 | NPC1 (1.00) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL8809242 | 0.78 | RAB9A (0.58) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL13531827 | 0.77 | NPC1 (0.89) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL13435257 | 0.77 | NPC1 (0.89) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL9642715 | 0.77 | NPC1 (0.89) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL29905043 | 0.76 | NPC1 (0.79) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL2057627 | 0.76 | NPC1 (0.79) | NPC1RAB9ARECQLCYP1A2CYP2D6 | |
| SCHEMBL1340747 | 0.74 | RAB9A (0.83) | NPC1RAB9ARECQLALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091265-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-10188682-B2 | Medicament for liver regeneration and for treatment of liver failure | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-01-29 | — | — | US | disclosed |
| EP-2694652-B1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-20160022742-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160022742-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-9186381-B2 | Medicament for liver regeneration and for treatment of liver failure | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9186381-B2 | Medicament for liver regeneration and for treatment of liver failure | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20140141510-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140141510-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022742-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | NPC1 3147/4885RAB9A 4262/4885RECQL 3372/4885 |
| US-20140141510-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | NPC1 3147/4885RAB9A 4262/4885RECQL 3372/4885 |
| US-20190091265-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | NPC1 3147/4885RAB9A 4262/4885RECQL 3372/4885 |
| US-10188682-B2 | Medicament for liver regeneration and for treatment of liver failure | PYGL, HNF4A, ATF1 | NPC1 3147/4885RAB9A 4262/4885RECQL 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.